What Is the First-Line Treatment for Cardiac Sarcoidosis?
Cardiac sarcoidosis involves active granulomatous inflammation of the myocardium and can manifest as arrhythmias, heart block, or heart failure. A structured first-line treatment approach with defined monitoring targets is central to managing this condition.
Treatment Approach
Corticosteroids are the established first-line treatment for cardiac sarcoidosis. In cases of more severe clinical presentation, or when tolerability at moderate to high corticosteroid doses is a concern, initial combination with a steroid-sparing agent may be considered.
Monitoring & Treatment Goals
Response is assessed at 2 to 6 months. Success is defined by improvement or resolution of arrhythmias, heart block, or heart failure, together with decreased or resolved myocardial inflammation on cardiac FDG-PET imaging.
References
DOI: 10.1161/CIR.0000000000001240
- Corticosteroids are currently considered the first-line treatment for individuals with CS.
- Corticosteroids are initiated at doses of 30 to 40 mg/d of prednisone equivalent because there is no demonstrated benefit with higher starting doses.
- Initial combination therapy of corticosteroids with a steroid-sparing agent can be considered in severe clinical presentations or in individuals intolerant of moderate to high doses of corticosteroids.
- The response to treatment is measured in 2 ways: (1) improvement or resolution of the clinical presentation of arrhythmias, heart block, or HF and (2) reduction in the degree of active granulomatous inflammation in the myocardium.
- Although the optimal timing and frequency of surveillance FDG-PET scans during active treatment while immunosuppression therapy is being adjusted are not well established, 3- to 6-month intervals are typically used.